ethyl 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate | 1174644-62-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate
• 英文别名: 8-methyl-5,6,7,8-tetrahydro-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester
• CAS: 1174644-62-2
• 化学式: C₁₀H₁₅N₃O₂
• 分子量: 209.248
• InChiKey: JRWLLTIYPLXGPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate 在 二异丁基氢化铝 、 sodium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 tert-butyl 2-formyl-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
  [FR] COMPOSÉS HÉTÉROCYCLIQUES À UTILISER DANS LE TRAITEMENT DU CANCER

  摘要：

  The invention relates to heterocyclic derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.

  公开号：

  WO2023067353A1
• 作为产物：
  描述：

  ethyl 8-methylimidazo[1,2-a]pyrazine-2-carboxylate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 50.0 ℃ 、344.75 kPa 条件下， 生成 ethyl 8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-2-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
  [FR] COMPOSÉS HÉTÉROCYCLIQUES À UTILISER DANS LE TRAITEMENT DU CANCER

  摘要：

  The invention relates to heterocyclic derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation.

  公开号：

  WO2023067353A1

文献信息

• Pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2085398A1

  公开（公告）日：2009-08-05

  The invention relates to pyrazolopyrimidine derivatives of Formula I wherein R1 represents chloro or bromo; A represents as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  本发明涉及以下式子的吡唑嘧啶衍生物（I）： 其中R1代表氯或溴； A代表 以及其药学上可接受的盐。本发明还涉及制备这种化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。
• PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE
  申请人：Henrich Markus

  公开号：US20110003820A1

  公开（公告）日：2011-01-06

  The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  本发明涉及吡唑并嘧啶衍生物及其药学上可接受的盐。本发明还涉及制备这些化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。
• 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2090576A1

  公开（公告）日：2009-08-19

  The invention relates to 6-halo-pyrazolo[1,5-a]pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. wherein A represents -NR3R4 with R3 and R4 as described herein.

  本发明涉及式（I）的6-卤代吡唑并[1,5-a]吡啶以及其药学上可接受的盐。本发明还涉及制备这些化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。 其中，A表示-NR3R4，其中R3和R4如本文所述。
• [EN] PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE<br/>[FR] PYRAZOLOPYRIMIDINES, LEUR MÉTHODE DE PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2009095254A1

  公开（公告）日：2009-08-06

  The invention relates to pyrazolopyrimidine derivatives of Formula (I) wherein R1 represents chloro or bromo; A represents (a); (b); (c); (d); or (e), as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
• [EN] 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS<br/>[FR] 6-HALO-PYRAZOLO[1,5-A]PYRIDINES, LEUR MÉTHODE DE PRÉPARATION ET LEUR UTILISATION COMME MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE (MGLUR)
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2009095253A1

  公开（公告）日：2009-08-06

  The invention relates to 6-halo-pyrazolo[1, 5-a] pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.